<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02050841</url>
  </required_header>
  <id_info>
    <org_study_id>LAS-212</org_study_id>
    <nct_id>NCT02050841</nct_id>
  </id_info>
  <brief_title>Octaplas Pediatric Plasma Replacement Trial</brief_title>
  <official_title>An Open-label, Multicenter, Post-Marketing Requirement (PMR) Study to Investigate the Safety, Tolerability and Efficacy of Octaplas in the Management of Pediatric Patients Who Require Replacement of Multiple Coagulation Factors.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Octapharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Octapharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the safety, tolerability and efficacy of octaplas
      in pediatric patients who require replacement of multiple coagulation factors. Replacement of
      multiple coagulation factors in pediatric patients with acquired deficiencies due to liver
      disease and/or in pediatric patients requiring cardiac surgery or liver surgery.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">December 4, 2017</completion_date>
  <primary_completion_date type="Actual">December 4, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Drug Reactions (e.g., Allergic Reactions, TEs, TEEs (Thromboembolic Events) and Hyperfibrinolytic Events)</measure>
    <time_frame>up to 6 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Monitoring of Clinically Significant Changes in White Blood Cells</measure>
    <time_frame>up to 6 days</time_frame>
    <description>Assesses Pre- and Post-infusion for Infusion Episode 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Monitoring of Clinically Significant Changes in Red Blood Cells</measure>
    <time_frame>up to 6 days</time_frame>
    <description>Assesses Pre- and Post-infusion for Infusion Episode 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Monitoring of Clinically Significant Changes in Hemoglobin</measure>
    <time_frame>up to 6 days</time_frame>
    <description>Assesses Pre- and Post-infusion for Infusion Episode 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Monitoring of Clinically Significant Changes in Hematocrit</measure>
    <time_frame>up to 6 days</time_frame>
    <description>Assesses Pre- and Post-infusion for Infusion Episode 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Monitoring of Clinically Significant Changes in Mean Corpuscular Volume (MCV)</measure>
    <time_frame>up to 6 days</time_frame>
    <description>Assesses Pre- and Post-infusion for Infusion Episode 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Monitoring of Clinically Significant Changes in Mean Corpuscular Hemoglobin (MCH)</measure>
    <time_frame>up to 6 days</time_frame>
    <description>Assesses Pre- and Post-infusion for Infusion Episode 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Monitoring of Clinically Significant Changes in Mean Corpuscular Hemoglobin Concentration (MCHC)</measure>
    <time_frame>up to 6 days</time_frame>
    <description>Assesses Pre- and Post-infusion for Infusion Episode 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Monitoring of Clinically Significant Changes in Red Cell Distribution Width (RDW)</measure>
    <time_frame>up to 6 days</time_frame>
    <description>Assesses Pre- and Post-infusion for Infusion Episode 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Monitoring of Clinically Significant Changes in Platelets</measure>
    <time_frame>up to 6 days</time_frame>
    <description>Assesses Pre- and Post-infusion for Infusion Episode 1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Changes in Hemostatic Parameters as Measured by the Following: International Normalized Ratio (INR)</measure>
    <time_frame>up to 6 days</time_frame>
    <description>This hemostatic parameter is figured out in the lab and helps to diagnose a bleeding disorder or excessive clotting disorder. The change of INR before and after 1st Octaplas infusion was scrutinized by analyzing the shifts between the classifications given below.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Changes in Hemostatic Parameters as Measured by the Following: Prothrombin Time (PT)</measure>
    <time_frame>up to 6 days</time_frame>
    <description>This hemostatic parameter is figured out in the lab and measures the time it takes for your blood to clot (the higher the PT the longer it takes your blood to clot). The change of PT before and after 1st Octaplas infusion was scrutinized by analyzing the shifts between the classifications given below.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Changes in Hemostatic Parameters as Measured by the Following: Thromboelastography (TEG) or Thromboelastometry (ROTEM).</measure>
    <time_frame>up to 6 days</time_frame>
    <description>TEG and ROTEM are methods of testing the efficiency of blood coagulation. The results were compared by looking at potential trends from TEG and ROTEM between pre-infusion vs post-infusion time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Changes in Hemostatic Parameters as Measured by the Following: Activated Partial Thromboplastin Time (aPTT)</measure>
    <time_frame>up to 6 days</time_frame>
    <description>aPTT measures the length of time (in seconds) that it takes for clotting to occur in a test cube. The higher the number of seconds the longer it takes the blood to clot. The changes between pre - and post infusion were analyzed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume (Dose in mL/kg) of Octaplas Used Per Infusion Episode for Each Patient.</measure>
    <time_frame>up to 6 days</time_frame>
    <description>Normal infusion: Replacement of multiple clotting factors Bypass priming: Limit hemodilution and reduce transfusion requirements Bypass warming up: Rewarm patients suffering from hypothermia during the surgery process</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medically Significant Changes in Blood Pressure</measure>
    <time_frame>up to 6 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medically Significant Changes in Heart Rate</measure>
    <time_frame>up to 6 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medically Significant Changes in Respiratory Rate</measure>
    <time_frame>up to 6 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medically Significant Changes in Oxygen Saturation</measure>
    <time_frame>up to 6 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medically Significant Changes in Body Temperature</measure>
    <time_frame>up to 6 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Count of Investigator's Assessment of Overall Safety Observed for Patients by Category (Assessed to Have Overall Safety of 'Excellent', Assessed to Have Overall Safety of 'Moderate', Assessed to Have Overall Safety of 'Poor')</measure>
    <time_frame>up to 6 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Liver Surgery</condition>
  <condition>Liver Dysfunction</condition>
  <condition>Coagulopathy</condition>
  <condition>Cardiac Surgery</condition>
  <arm_group>
    <arm_group_label>Octaplas</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Qualified patients will receive Octaplas as per protocol.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>octaplas</intervention_name>
    <description>Octaplas S/D Plasma</description>
    <arm_group_label>Octaplas</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient requiring liver or cardiac surgery and/or patient with liver dysfunction
             associated with coagulopathy in whom replacement of multiple coagulation factors is
             required.

          2. Voluntarily given, written and signed informed consent by the patient's legal
             representative(s) or guardian(s). Children deemed old enough by the
             Investigator/institution to understand the risks and benefits of the study should also
             be made aware of the risks/benefits of the study and provide written assent.

          3. Male or female patient ≤ 16 years of age.

        Exclusion Criteria:

          1. Patient with known homozygous congenital deficiency of protein S.

          2. Patient has a history of hypersensitivity reaction to blood or plasma-derived products
             or to any excipient of the investigational product.

          3. Patient has an already known IgA (Immunoglobulin A) deficiency with documented
             antibodies against IgA.

          4. Patient has a congenital factor deficiency or platelet disorder requiring plasma
             treatment.

          5. Patient is currently participating in another study investigating a new drug product
             or another interventional clinical study that may impact coagulation factors or has
             participated during the last three (3) months.

          6. Patient received FFP (Fresh Frozen Plasma), FP24 (Plasma frozen within 24 hours of
             collection) or any other plasma product other than Octaplas within the last 72 hours
             (cryoprecipitate and albumin are not exclusionary) prior to first Octaplas infusion.

          7. Patient is on ECMO (Extracorporeal Membrane Oxygenation) when plasma is ordered by the
             treating physician for the first infusion episode.

          8. Patient is pregnant.

          9. Patient is predicted to require massive blood transfusion defined as more than 40 mL
             per kilogram of all blood products in a 24-hour period

         10. Patient is receiving plasma exchange, therapeutic plasma exchange (TPE) or
             plasmapheresis.

         11. Patient is a premature neonate defined as less than 37 weeks gestation.

         12. Cardiac surgery patients who develop the need for plasma replacement greater than 72
             hours after the end of the associated cardiac surgery and do not have coagulopathy due
             to hepatic dysfunction.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wolfgang Frenzel</last_name>
    <role>Study Director</role>
    <affiliation>International Medical Director</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Octapharma Research Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Octapharma Research Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Octapharma Research Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Octapharma Research Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>January 21, 2014</study_first_submitted>
  <study_first_submitted_qc>January 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 31, 2014</study_first_posted>
  <results_first_submitted>January 7, 2019</results_first_submitted>
  <results_first_submitted_qc>March 21, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">March 25, 2019</results_first_posted>
  <last_update_submitted>June 9, 2020</last_update_submitted>
  <last_update_submitted_qc>June 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pediatric</keyword>
  <keyword>patients</keyword>
  <keyword>replacement</keyword>
  <keyword>coagulation factors</keyword>
  <keyword>plasma</keyword>
  <keyword>s/d plasma</keyword>
  <keyword>Octaplas</keyword>
  <keyword>plasma replacement</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 19, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/41/NCT02050841/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 1, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/41/NCT02050841/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Octaplas</title>
          <description>Qualified patients will receive Octaplas as per protocol.
octaplas: Octaplas S/D Plasma</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Octaplas</title>
          <description>Qualified patients will receive Octaplas as per protocol.
octaplas: Octaplas S/D Plasma</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.0" spread="3.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ABO Blood Group</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>A</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>B</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>AB</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>O</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>centimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78.1" spread="30.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13.66" spread="21.589"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16.88" spread="5.421"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Drug Reactions (e.g., Allergic Reactions, TEs, TEEs (Thromboembolic Events) and Hyperfibrinolytic Events)</title>
        <time_frame>up to 6 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Octaplas</title>
            <description>Qualified patients will receive Octaplas as per protocol.
octaplas: Octaplas S/D Plasma</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Drug Reactions (e.g., Allergic Reactions, TEs, TEEs (Thromboembolic Events) and Hyperfibrinolytic Events)</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any SAE related to Octaplas</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any ADR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any ADR, SAE, HFE TEE, or TE leading to withdrawal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any ADR, SAE, HFE, TEE, or TE leading to death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any study death related to Octaplas</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Monitoring of Clinically Significant Changes in White Blood Cells</title>
        <description>Assesses Pre- and Post-infusion for Infusion Episode 1</description>
        <time_frame>up to 6 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Children &gt;2 Years</title>
            <description>Qualified patients will receive Octaplas as per protocol.
octaplas: Octaplas S/D Plasma</description>
          </group>
          <group group_id="O2">
            <title>Infants ≤2 Years</title>
            <description>Qualified patients will receive Octaplas as per protocol.
octaplas: Octaplas S/D Plasma</description>
          </group>
        </group_list>
        <measure>
          <title>Monitoring of Clinically Significant Changes in White Blood Cells</title>
          <description>Assesses Pre- and Post-infusion for Infusion Episode 1</description>
          <units>10^3/µL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" lower_limit="-4.7" upper_limit="28.3"/>
                    <measurement group_id="O2" value="2.05" lower_limit="-12.3" upper_limit="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Monitoring of Clinically Significant Changes in Red Blood Cells</title>
        <description>Assesses Pre- and Post-infusion for Infusion Episode 1</description>
        <time_frame>up to 6 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Children &gt;2 Years</title>
            <description>Qualified patients will receive Octaplas as per protocol.
octaplas: Octaplas S/D Plasma</description>
          </group>
          <group group_id="O2">
            <title>Infants ≤2 Years</title>
            <description>Qualified patients will receive Octaplas as per protocol.
octaplas: Octaplas S/D Plasma</description>
          </group>
        </group_list>
        <measure>
          <title>Monitoring of Clinically Significant Changes in Red Blood Cells</title>
          <description>Assesses Pre- and Post-infusion for Infusion Episode 1</description>
          <units>10^6/µL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.34" lower_limit="-1.4" upper_limit="0.6"/>
                    <measurement group_id="O2" value="-0.06" lower_limit="-1.8" upper_limit="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Monitoring of Clinically Significant Changes in Hemoglobin</title>
        <description>Assesses Pre- and Post-infusion for Infusion Episode 1</description>
        <time_frame>up to 6 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Children &gt;2 Years</title>
            <description>Qualified patients will receive Octaplas as per protocol.
octaplas: Octaplas S/D Plasma</description>
          </group>
          <group group_id="O2">
            <title>Infants ≤2 Years</title>
            <description>Qualified patients will receive Octaplas as per protocol.
octaplas: Octaplas S/D Plasma</description>
          </group>
        </group_list>
        <measure>
          <title>Monitoring of Clinically Significant Changes in Hemoglobin</title>
          <description>Assesses Pre- and Post-infusion for Infusion Episode 1</description>
          <units>g/dL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.70" lower_limit="-3.9" upper_limit="2.7"/>
                    <measurement group_id="O2" value="0.80" lower_limit="-4.6" upper_limit="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Monitoring of Clinically Significant Changes in Hematocrit</title>
        <description>Assesses Pre- and Post-infusion for Infusion Episode 1</description>
        <time_frame>up to 6 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Children &gt;2 Years</title>
            <description>Qualified patients will receive Octaplas as per protocol.
octaplas: Octaplas S/D Plasma</description>
          </group>
          <group group_id="O2">
            <title>Infants ≤2 Years</title>
            <description>Qualified patients will receive Octaplas as per protocol.
octaplas: Octaplas S/D Plasma</description>
          </group>
        </group_list>
        <measure>
          <title>Monitoring of Clinically Significant Changes in Hematocrit</title>
          <description>Assesses Pre- and Post-infusion for Infusion Episode 1</description>
          <units>volume percentage of RBC in blood</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.35" lower_limit="-10.8" upper_limit="6.5"/>
                    <measurement group_id="O2" value="1.35" lower_limit="-14.6" upper_limit="16.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Monitoring of Clinically Significant Changes in Mean Corpuscular Volume (MCV)</title>
        <description>Assesses Pre- and Post-infusion for Infusion Episode 1</description>
        <time_frame>up to 6 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Children &gt;2 Years</title>
            <description>Qualified patients will receive Octaplas as per protocol.
octaplas: Octaplas S/D Plasma</description>
          </group>
          <group group_id="O2">
            <title>Infants ≤2 Years</title>
            <description>Qualified patients will receive Octaplas as per protocol.
octaplas: Octaplas S/D Plasma</description>
          </group>
        </group_list>
        <measure>
          <title>Monitoring of Clinically Significant Changes in Mean Corpuscular Volume (MCV)</title>
          <description>Assesses Pre- and Post-infusion for Infusion Episode 1</description>
          <units>fL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" lower_limit="-5.4" upper_limit="6.3"/>
                    <measurement group_id="O2" value="1.85" lower_limit="-22.8" upper_limit="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Monitoring of Clinically Significant Changes in Mean Corpuscular Hemoglobin (MCH)</title>
        <description>Assesses Pre- and Post-infusion for Infusion Episode 1</description>
        <time_frame>up to 6 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Children &gt;2 Years</title>
            <description>Qualified patients will receive Octaplas as per protocol.
octaplas: Octaplas S/D Plasma</description>
          </group>
          <group group_id="O2">
            <title>Infants ≤2 Years</title>
            <description>Qualified patients will receive Octaplas as per protocol.
octaplas: Octaplas S/D Plasma</description>
          </group>
        </group_list>
        <measure>
          <title>Monitoring of Clinically Significant Changes in Mean Corpuscular Hemoglobin (MCH)</title>
          <description>Assesses Pre- and Post-infusion for Infusion Episode 1</description>
          <units>pg</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.85" lower_limit="-1.8" upper_limit="2.9"/>
                    <measurement group_id="O2" value="1.00" lower_limit="-8.3" upper_limit="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Monitoring of Clinically Significant Changes in Mean Corpuscular Hemoglobin Concentration (MCHC)</title>
        <description>Assesses Pre- and Post-infusion for Infusion Episode 1</description>
        <time_frame>up to 6 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Children &gt;2 Years</title>
            <description>Qualified patients will receive Octaplas as per protocol.
octaplas: Octaplas S/D Plasma</description>
          </group>
          <group group_id="O2">
            <title>Infants ≤2 Years</title>
            <description>Qualified patients will receive Octaplas as per protocol.
octaplas: Octaplas S/D Plasma</description>
          </group>
        </group_list>
        <measure>
          <title>Monitoring of Clinically Significant Changes in Mean Corpuscular Hemoglobin Concentration (MCHC)</title>
          <description>Assesses Pre- and Post-infusion for Infusion Episode 1</description>
          <units>g/dL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.15" lower_limit="-0.9" upper_limit="4.2"/>
                    <measurement group_id="O2" value="0.20" lower_limit="-1.2" upper_limit="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Monitoring of Clinically Significant Changes in Red Cell Distribution Width (RDW)</title>
        <description>Assesses Pre- and Post-infusion for Infusion Episode 1</description>
        <time_frame>up to 6 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Children &gt;2 Years</title>
            <description>Qualified patients will receive Octaplas as per protocol.
octaplas: Octaplas S/D Plasma</description>
          </group>
          <group group_id="O2">
            <title>Infants ≤2 Years</title>
            <description>Qualified patients will receive Octaplas as per protocol.
octaplas: Octaplas S/D Plasma</description>
          </group>
        </group_list>
        <measure>
          <title>Monitoring of Clinically Significant Changes in Red Cell Distribution Width (RDW)</title>
          <description>Assesses Pre- and Post-infusion for Infusion Episode 1</description>
          <units>% variation of RBC size</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.10" lower_limit="-3.9" upper_limit="3.0"/>
                    <measurement group_id="O2" value="0.40" lower_limit="-2.1" upper_limit="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Monitoring of Clinically Significant Changes in Platelets</title>
        <description>Assesses Pre- and Post-infusion for Infusion Episode 1</description>
        <time_frame>up to 6 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Children &gt;2 Years</title>
            <description>Qualified patients will receive Octaplas as per protocol.
octaplas: Octaplas S/D Plasma</description>
          </group>
          <group group_id="O2">
            <title>Infants ≤2 Years</title>
            <description>Qualified patients will receive Octaplas as per protocol.
octaplas: Octaplas S/D Plasma</description>
          </group>
        </group_list>
        <measure>
          <title>Monitoring of Clinically Significant Changes in Platelets</title>
          <description>Assesses Pre- and Post-infusion for Infusion Episode 1</description>
          <units>10^3/µL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-105.5" lower_limit="-210.0" upper_limit="15.0"/>
                    <measurement group_id="O2" value="-167.00" lower_limit="-410.0" upper_limit="215.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinically Significant Changes in Hemostatic Parameters as Measured by the Following: International Normalized Ratio (INR)</title>
        <description>This hemostatic parameter is figured out in the lab and helps to diagnose a bleeding disorder or excessive clotting disorder. The change of INR before and after 1st Octaplas infusion was scrutinized by analyzing the shifts between the classifications given below.</description>
        <time_frame>up to 6 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Octaplas</title>
            <description>Qualified patients will receive Octaplas as per protocol.
octaplas: Octaplas S/D Plasma</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Changes in Hemostatic Parameters as Measured by the Following: International Normalized Ratio (INR)</title>
          <description>This hemostatic parameter is figured out in the lab and helps to diagnose a bleeding disorder or excessive clotting disorder. The change of INR before and after 1st Octaplas infusion was scrutinized by analyzing the shifts between the classifications given below.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Shift from Not Clinically Significant to Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remained Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remained Not Clinically Significant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Shift from Normal to Not Clinically Significant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Shift to or from Clinically Significant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinically Significant Changes in Hemostatic Parameters as Measured by the Following: Prothrombin Time (PT)</title>
        <description>This hemostatic parameter is figured out in the lab and measures the time it takes for your blood to clot (the higher the PT the longer it takes your blood to clot). The change of PT before and after 1st Octaplas infusion was scrutinized by analyzing the shifts between the classifications given below.</description>
        <time_frame>up to 6 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Octaplas</title>
            <description>Qualified patients will receive Octaplas as per protocol.
octaplas: Octaplas S/D Plasma</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Changes in Hemostatic Parameters as Measured by the Following: Prothrombin Time (PT)</title>
          <description>This hemostatic parameter is figured out in the lab and measures the time it takes for your blood to clot (the higher the PT the longer it takes your blood to clot). The change of PT before and after 1st Octaplas infusion was scrutinized by analyzing the shifts between the classifications given below.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Shift from Not Clinically Significant to Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remained Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remained Not Clinically Significant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Shift from Normal to Not Clinically Significant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Shift to or from Clinically Significant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinically Significant Changes in Hemostatic Parameters as Measured by the Following: Thromboelastography (TEG) or Thromboelastometry (ROTEM).</title>
        <description>TEG and ROTEM are methods of testing the efficiency of blood coagulation. The results were compared by looking at potential trends from TEG and ROTEM between pre-infusion vs post-infusion time points.</description>
        <time_frame>up to 6 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>EPL30-TEG</title>
            <description>Number of Participants With Clinically Significant Changes in Hemostatic Parameters as Measured by EPL30-TEG (estimated percent lysis)</description>
          </group>
          <group group_id="O2">
            <title>ML30-ROTEM</title>
            <description>Number of Participants WithClinically Significant Changes in Hemostatic Parameters as Measured byThromboelastometry (ROTEM).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Changes in Hemostatic Parameters as Measured by the Following: Thromboelastography (TEG) or Thromboelastometry (ROTEM).</title>
          <description>TEG and ROTEM are methods of testing the efficiency of blood coagulation. The results were compared by looking at potential trends from TEG and ROTEM between pre-infusion vs post-infusion time points.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Shift from Not Clinically Significant to Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remained Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remained Not Clinically Significant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Shift from Normal to Not Clinically Significant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Shift to or from Clinically Significant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinically Significant Changes in Hemostatic Parameters as Measured by the Following: Activated Partial Thromboplastin Time (aPTT)</title>
        <description>aPTT measures the length of time (in seconds) that it takes for clotting to occur in a test cube. The higher the number of seconds the longer it takes the blood to clot. The changes between pre - and post infusion were analyzed</description>
        <time_frame>up to 6 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Octaplas</title>
            <description>Qualified patients will receive Octaplas as per protocol.
octaplas: Octaplas S/D Plasma</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Changes in Hemostatic Parameters as Measured by the Following: Activated Partial Thromboplastin Time (aPTT)</title>
          <description>aPTT measures the length of time (in seconds) that it takes for clotting to occur in a test cube. The higher the number of seconds the longer it takes the blood to clot. The changes between pre - and post infusion were analyzed</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>From (NCS) Not Clinically Significant to Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remained Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remained Not Clinically Significant (NCS)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Shift from Normal to Not Clinically Significant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NCS to Clinically Significant Shift</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clinically Significant to NCS shift</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Volume (Dose in mL/kg) of Octaplas Used Per Infusion Episode for Each Patient.</title>
        <description>Normal infusion: Replacement of multiple clotting factors Bypass priming: Limit hemodilution and reduce transfusion requirements Bypass warming up: Rewarm patients suffering from hypothermia during the surgery process</description>
        <time_frame>up to 6 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Octaplas</title>
            <description>Qualified patients will receive Octaplas as per protocol.
octaplas: Octaplas S/D Plasma</description>
          </group>
        </group_list>
        <measure>
          <title>Volume (Dose in mL/kg) of Octaplas Used Per Infusion Episode for Each Patient.</title>
          <description>Normal infusion: Replacement of multiple clotting factors Bypass priming: Limit hemodilution and reduce transfusion requirements Bypass warming up: Rewarm patients suffering from hypothermia during the surgery process</description>
          <units>mL/kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Normal Infusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15" spread="14.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bypass Priming</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.2" spread="7.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bypass Warming Up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.9" spread="5.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Medically Significant Changes in Blood Pressure</title>
        <time_frame>up to 6 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Octaplas - Pre-Infusion</title>
            <description>Pre-Infusion Vital Signs</description>
          </group>
          <group group_id="O2">
            <title>Octaplas - Post-Infusion</title>
            <description>Post-Infusion Vital Signs</description>
          </group>
        </group_list>
        <measure>
          <title>Medically Significant Changes in Blood Pressure</title>
          <units>mm of Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Systolic Blood Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.66" spread="16.901"/>
                    <measurement group_id="O2" value="79.96" spread="16.437"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic Blood Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.28" spread="10.031"/>
                    <measurement group_id="O2" value="50.00" spread="11.648"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Medically Significant Changes in Heart Rate</title>
        <time_frame>up to 6 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Octaplas - Pre-Infusion</title>
            <description>Pre-Infusion Vital Signs</description>
          </group>
          <group group_id="O2">
            <title>Octaplas - Post-Infusion</title>
            <description>Post-Infusion Vital Signs</description>
          </group>
        </group_list>
        <measure>
          <title>Medically Significant Changes in Heart Rate</title>
          <units>beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122.86" spread="30.528"/>
                    <measurement group_id="O2" value="132.80" spread="24.439"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Medically Significant Changes in Respiratory Rate</title>
        <time_frame>up to 6 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Octaplas - Pre-Infusion</title>
            <description>Pre-Infusion Vital Signs</description>
          </group>
          <group group_id="O2">
            <title>Octaplas - Post-Infusion</title>
            <description>Post-Infusion Vital Signs</description>
          </group>
        </group_list>
        <measure>
          <title>Medically Significant Changes in Respiratory Rate</title>
          <units>breaths/minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.27" spread="7.335"/>
                    <measurement group_id="O2" value="23.79" spread="6.702"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Medically Significant Changes in Oxygen Saturation</title>
        <time_frame>up to 6 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Octaplas - Pre-Infusion</title>
            <description>Pre-Infusion Vital Signs</description>
          </group>
          <group group_id="O2">
            <title>Octaplas - Post-Infusion</title>
            <description>Post-Infusion Vital Signs</description>
          </group>
        </group_list>
        <measure>
          <title>Medically Significant Changes in Oxygen Saturation</title>
          <units>% oxygen in blood</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.86" spread="5.564"/>
                    <measurement group_id="O2" value="98.33" spread="3.204"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Medically Significant Changes in Body Temperature</title>
        <time_frame>up to 6 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Octaplas - Pre-Infusion</title>
            <description>Pre-Infusion Vital Signs</description>
          </group>
          <group group_id="O2">
            <title>Octaplas - Post-Infusion</title>
            <description>Post-Infusion Vital Signs</description>
          </group>
        </group_list>
        <measure>
          <title>Medically Significant Changes in Body Temperature</title>
          <units>units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.60" spread="2.023"/>
                    <measurement group_id="O2" value="36.50" spread="1.597"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Count of Investigator's Assessment of Overall Safety Observed for Patients by Category (Assessed to Have Overall Safety of 'Excellent', Assessed to Have Overall Safety of 'Moderate', Assessed to Have Overall Safety of 'Poor')</title>
        <time_frame>up to 6 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Octaplas</title>
            <description>Qualified patients will receive Octaplas as per protocol.
octaplas: Octaplas S/D Plasma</description>
          </group>
        </group_list>
        <measure>
          <title>Count of Investigator's Assessment of Overall Safety Observed for Patients by Category (Assessed to Have Overall Safety of 'Excellent', Assessed to Have Overall Safety of 'Moderate', Assessed to Have Overall Safety of 'Poor')</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Assessed to have overall safety of 'excellent'</title>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Assessed to have overall safety of 'moderate'</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Assessed to have overall safety of 'poor'</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected for each participant over the course of 6 days</time_frame>
      <desc>Any of the following drug safety information was collected after the start of the first infusion episode:
Serious adverse events
Adverse drug reactions temporally associated with administration of the investigational product
Adverse events that fall into the category of TEs, TEEs and hyperfibrinolytic events
Post-treatment related safety reports, pregnancies, drug overdose, interaction, abuse, misuse, medication error, lack of efficacy</desc>
      <group_list>
        <group group_id="E1">
          <title>Octaplas</title>
          <description>Qualified patients will receive Octaplas as per protocol.
octaplas: Octaplas S/D Plasma</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Intracardiac thrombus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Iatrogenic injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Portal vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Shock haemorrhagic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Haemorrhage coronary artery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michael Eppolito</name_or_title>
      <organization>Octapharma</organization>
      <phone>2016041155</phone>
      <email>michael.eppolito@octapharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

